Format
Sort by
Items per page

Send to

Choose Destination

Selected items

Items: 14

1.

Role of HIV infection duration and CD4 cell level at initiation of combination anti-retroviral therapy on risk of failure.

Lodi S, Phillips A, Fidler S, Hawkins D, Gilson R, McLean K, Fisher M, Post F, Johnson AM, Walker-Nthenda L, Dunn D, Porter K; UK Register of HIV..

PLoS One. 2013 Sep 24;8(9):e75608. doi: 10.1371/journal.pone.0075608. eCollection 2013.

2.

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion--reply.

Porter K, Lodi S, Meyer L.

JAMA Intern Med. 2013 Mar 25;173(6):476-7. doi: 10.1001/jamainternmed.2013.2784. No abstract available.

PMID:
23529555
3.

Rate of CD4 decline and HIV-RNA change following HIV seroconversion in men who have sex with men: a comparison between the Beijing PRIMO and CASCADE cohorts.

Huang X, Lodi S, Fox Z, Li W, Phillips A, Porter K, Lutsar I, Kelleher A, Li N, Xu X, Wu H, Johnson AM; Beijing PRIMO cohort study.; CASCADE Collaboration in EuroCoord..

J Acquir Immune Defic Syndr. 2013 Apr 1;62(4):441-6. doi: 10.1097/QAI.0b013e31827f5c9a.

PMID:
23221982
4.

Risk of tuberculosis following HIV seroconversion in high-income countries.

Lodi S, del Amo J, d'Arminio Monforte A, Abgrall S, Sabin C, Morrison C, Furrer H, Muga R, Porter K, Girardi E; CASCADE collaboration in EuroCoord..

Thorax. 2013 Mar;68(3):207-13. doi: 10.1136/thoraxjnl-2012-201740. Epub 2012 Oct 31.

PMID:
23117980
5.

Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion.

Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K.

Arch Intern Med. 2012 Sep 10;172(16):1252-5. doi: 10.1001/archinternmed.2012.2719.

PMID:
22826124
6.

The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study.

Cain LE, Phillips A, Lodi S, Sabin C, Bansi L, Justice A, Tate J, Logan R, Robins JM, Sterne JA, van Sighem A, de Wolf F, Bucher HC, Elzi L, Touloumi G, Vourli G, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Pérez-Hoyos S, Muga R, Abgrall S, Costagliola D, Hernán MA; HIV-CAUSAL Collaboration..

AIDS. 2012 Aug 24;26(13):1691-705.

7.

Impact of antiretroviral therapy on tuberculosis incidence among HIV-positive patients in high-income countries.

del Amo J, Moreno S, Bucher HC, Furrer H, Logan R, Sterne J, Pérez-Hoyos S, Jarrín I, Phillips A, Lodi S, van Sighem A, de Wolf W, Sabin C, Bansi L, Justice A, Goulet J, Miró JM, Ferrer E, Meyer L, Seng R, Toulomi G, Gargalianos P, Costagliola D, Abgrall S, Hernán MA; HIV-CAUSAL Collaboration..

Clin Infect Dis. 2012 May;54(9):1364-72. doi: 10.1093/cid/cis203. Epub 2012 Mar 28.

8.

Time from human immunodeficiency virus seroconversion to reaching CD4+ cell count thresholds <200, <350, and <500 Cells/mm³: assessment of need following changes in treatment guidelines.

Lodi S, Phillips A, Touloumi G, Geskus R, Meyer L, Thiébaut R, Pantazis N, Amo JD, Johnson AM, Babiker A, Porter K; CASCADE Collaboration in EuroCoord..

Clin Infect Dis. 2011 Oct;53(8):817-25. doi: 10.1093/cid/cir494.

PMID:
21921225
9.

When to initiate combined antiretroviral therapy to reduce mortality and AIDS-defining illness in HIV-infected persons in developed countries: an observational study.

HIV-CAUSAL Collaboration., Cain LE, Logan R, Robins JM, Sterne JA, Sabin C, Bansi L, Justice A, Goulet J, van Sighem A, de Wolf F, Bucher HC, von Wyl V, Esteve A, Casabona J, del Amo J, Moreno S, Seng R, Meyer L, Perez-Hoyos S, Muga R, Lodi S, Lanoy E, Costagliola D, Hernan MA.

Ann Intern Med. 2011 Apr 19;154(8):509-15. doi: 10.7326/0003-4819-154-8-201104190-00001.

10.

Design of cohort studies in chronic diseases using routinely collected databases when a prescription is used as surrogate outcome.

Lodi S, Carpenter J, Egger P, Evans S.

BMC Med Res Methodol. 2011 Apr 1;11:36. doi: 10.1186/1471-2288-11-36.

11.

CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era.

Lodi S, Phillips A, Touloumi G, Pantazis N, Bucher HC, Babiker A, Chêne G, Vanhems P, Porter K; CASCADE Collaboration..

AIDS. 2010 Nov 13;24(17):2697-704. doi: 10.1097/QAD.0b013e32833ef6c4.

PMID:
20885283
12.

Kaposi sarcoma incidence and survival among HIV-infected homosexual men after HIV seroconversion.

Lodi S, Guiguet M, Costagliola D, Fisher M, de Luca A, Porter K; CASCADE Collaboration..

J Natl Cancer Inst. 2010 Jun 2;102(11):784-92. doi: 10.1093/jnci/djq134. Epub 2010 May 4.

13.

Is there an anti-inflammatory effect of statins in rheumatoid arthritis? Analysis of a large routinely collected claims database.

Lodi S, Evans SJ, Egger P, Carpenter J.

Br J Clin Pharmacol. 2010 Jan;69(1):85-94. doi: 10.1111/j.1365-2125.2009.03560.x.

14.

The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals.

HIV-CAUSAL Collaboration., Ray M, Logan R, Sterne JA, Hernández-Díaz S, Robins JM, Sabin C, Bansi L, van Sighem A, de Wolf F, Costagliola D, Lanoy E, Bucher HC, von Wyl V, Esteve A, Casbona J, del Amo J, Moreno S, Justice A, Goulet J, Lodi S, Phillips A, Seng R, Meyer L, Pérez-Hoyos S, García de Olalla P, Hernán MA.

AIDS. 2010 Jan 2;24(1):123-37. doi: 10.1097/QAD.0b013e3283324283.

Supplemental Content

Support Center